↓ Skip to main content

Cost-utility analysis of Palivizumab for Respiratory Syncytial Virus infection prophylaxis in preterm infants: update based on the clinical evidence in Spain

Overview of attention for article published in BMC Infectious Diseases, October 2017
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (82nd percentile)
  • High Attention Score compared to outputs of the same age and source (88th percentile)

Mentioned by

policy
2 policy sources
twitter
7 X users
facebook
1 Facebook page

Citations

dimensions_citation
25 Dimensions

Readers on

mendeley
93 Mendeley